Emerging Evidence for Cardiorenal Protection with Sodium–Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabetes

Endocrinology and Metabolism Clinics of North America · Published 2026-05-22 · DOI 10.1016/j.ecl.2026.04.007

Authors (4)

Stuti Fernandes, Barbara Hettinger, Lynn Ang, Rodica Pop-Busui

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Fernandes, S., Hettinger, B., Ang, L., et al. (2026). Emerging Evidence for Cardiorenal Protection with Sodium–Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America. https://doi.org/10.1016/j.ecl.2026.04.007

Related articles